Peptide Graded

Semaglutide

Is Semaglutide safe?

Large trials; GI effects, boxed thyroid warning

AStrong human evidenceFDA approvedas of 2026-10-26

Nausea, diarrhea, vomiting and constipation are the common side effects. They hit a large share of users early in treatment and fade for most. In STEP 1, 4.5 percent stopped because of them. In SELECT, 16.6 percent stopped for adverse events versus 8.2 percent on placebo. Gallbladder disease is more frequent. Rapid weight loss itself causes gallstones, in part. The label carries a boxed warning about thyroid C-cell tumors seen in rodents. No human signal has been confirmed. The label bars use in people with a personal or family history of medullary thyroid cancer. Pancreatitis is listed as a risk. But the meta-analysis in diabetes did not find an excess. Slow stomach emptying has been linked to aspiration during anesthesia. One diabetes trial saw a small rise in diabetic retinopathy complications. The trials have also documented two practical concerns. Users lose lean mass alongside fat. And nearly everyone regains weight after stopping. 1235712

Read the full Semaglutide page

More on Semaglutide

Citations

  1. Ozempic (semaglutide) prescribing information, FDA, 2023 accessdata.fda.gov
  2. Wilding 2021, N Engl J Med: once-weekly semaglutide in adults with overweight or obesity (STEP 1) pubmed.ncbi.nlm.nih.gov
  3. Lincoff 2023, N Engl J Med: semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT) pubmed.ncbi.nlm.nih.gov
  4. Frías 2021, Lancet Diabetes Endocrinol: higher versus standard dose semaglutide in type 2 diabetes (SUSTAIN FORTE) pubmed.ncbi.nlm.nih.gov
  5. Diabetol Metab Syndr 2023: systematic review and meta-analysis of subcutaneous semaglutide in type 2 diabetes pubmed.ncbi.nlm.nih.gov
  6. Rubino 2022, JAMA: semaglutide versus liraglutide for weight loss (STEP 8) pubmed.ncbi.nlm.nih.gov
  7. Wegovy (semaglutide) prescribing information, DailyMed dailymed.nlm.nih.gov
  8. Rubino 2021, JAMA: continued semaglutide versus placebo for weight maintenance (STEP 4) pubmed.ncbi.nlm.nih.gov
  9. Deanfield 2024, Lancet: semaglutide in patients with obesity and heart failure, SELECT prespecified analysis pubmed.ncbi.nlm.nih.gov
  10. Lincoff 2023, N Engl J Med: SELECT trial (DOI record) doi.org
  11. Lancet 2025: semaglutide and cardiovascular outcomes by adiposity measures, SELECT prespecified analysis pubmed.ncbi.nlm.nih.gov
  12. Wilding 2022, Diabetes Obes Metab: weight regain after withdrawal of semaglutide, STEP 1 extension pubmed.ncbi.nlm.nih.gov
  13. Perkovic 2024, N Engl J Med: effects of semaglutide on chronic kidney disease in type 2 diabetes (FLOW) doi.org
  14. AJMC 2025: FDA approves semaglutide for MASH with fibrosis ajmc.com
  15. Healio 2026: FDA approves Wegovy pill, the first oral GLP-1 for obesity healio.com
  16. Jastreboff 2022, N Engl J Med: tirzepatide once weekly for obesity (SURMOUNT-1) pubmed.ncbi.nlm.nih.gov
  17. Karagiannis 2024, Diabetologia: tirzepatide versus semaglutide in type 2 diabetes, network meta-analysis pubmed.ncbi.nlm.nih.gov

Reference information only, not medical advice. Drawn from the Semaglutide article, fact-checked against the cited sources. No dosing anywhere on this site.